Towards universal access: scaling up priority HIV/AIDS interventions in the health sector Progress report 2009 Slide set – six summary data slides and

Towards universal access: scaling up priority HIV/AIDS interventions in the

health sector

Progress report 2009

Slide set – six summary data slides and all 40 figures from the report

Towards universal access: progress report 2009 | 18 April 20232 |

Increase in antiretroviral therapy in low- and middle-income countries, adults and children [combined], December 2007–December 2008

Increase in antiretroviral therapy in low- and middle-income countries, adults and children [combined], December 2007–December 2008

Geographical region Number of people receiving ARV

therapy

December 2008

Number of people receiving

ARV therapy

December 2007

Increasein one

year

Sub-Saharan Africa 2 925 000 2 100 000 39%

Latin America and the Caribbean 445 000 390 000 14%

East, South and South-East Asia 565 000 420 000 35%

Europe and Central Asia 85 000 54 000 39%

North Africa and the Middle East 10 000 7 000 43%

Total 4 030 000 [3.7–4.4 million]

2 970 000[2.7–3.3 million]

36%


Antiretroviral therapy coverage in low- and middle-income countries, adults and children [combined], December 2008

Antiretroviral therapy coverage in low- and middle-income countries, adults and children [combined], December 2008

Geographical region Estimated number of people receiving

ARV therapy

Estimated number of people

needing ARV therapy

Antiretroviral therapy

coverage



East, South and South-East Asia 565 000 1 500 000 37%



Total 4 030 000 [3.7–4.4 million]

9 500 000[8.6–10 million]

42%[40–47%]


Antiretroviral therapy coverage in low- and middle-income countries, adults (≥15 years), December 2008

Antiretroviral therapy coverage in low- and middle-income countries, adults (≥15 years), December 2008

Geographical region Reported number of adults (≥15

years) receiving ARV therapy

Estimated number of adults

needing ARV therapy


coverage



East, South and South-East Asia 537 000 1 500 000 36%



Total 3 755 000 8 800 000[8.1–9.5 million]

43%[39–46%]


Antiretroviral therapy coverage in low- and middle-income countries, children (0–14 years), December 2008

Antiretroviral therapy coverage in low- and middle-income countries, children (0–14 years), December 2008

Geographical region Reported number of children (0–14 years) receiving

ARV therapy

Estimated number of

children needing ARV therapy


coverage

Sub-Saharan Africa 224 900 640 000 35%




North Africa and the Middle East 400 6 700 6%

Total 275 700 730 000[580 000–880 000]

38%[31–47%]


Prevention of mother-to-child transmission coverage in low- and middle-income countries, December 2008

Prevention of mother-to-child transmission coverage in low- and middle-income countries, December 2008

Geographical region Reported number of pregnant

women living with HIV receiving

ARVs for PMTCT

Estimated number of

pregnant women living with HIV

needing ARVs for PMTCT

Prevention of mother-to-

child transmission

coverage

Sub-Saharan Africa 576 800 1 280 000 45%




North Africa and the Middle East <200 13 400 1%

Total 628 400 1 400 000[1.1–1.7 million]

45%[37–57%]


Number of people receiving antiretroviral therapy in low- and middle-income countries, by region, 2002–2008

Number of people receiving antiretroviral therapy in low- and middle-income countries, by region, 2002–2008

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

End 2002 End 2003 End 2004 End 2005 End 2006 End 2007 End 2008

Mill

ion

s

North Africa and the Middle East

Europe and Central Asia

East, South and South-East Asia

Latin America and the Caribbean

Sub-Saharan Africa


Fig. 2.1. Transaction volumes of rapid HIV tests, 2004–2008Fig. 2.1. Transaction volumes of rapid HIV tests, 2004–2008


Fig. 2.2. Reported number of health facilities providing HIV testing and counselling services in low- and middle-income countries with comparable data, by region, 2007 and 2008

Fig. 2.2. Reported number of health facilities providing HIV testing and counselling services in low- and middle-income countries with comparable data, by region, 2007 and 2008


Fig. 2.3. Percentage of women with HIV testing and counselling and percentage of women with secondary or

higher education, district comprehensive assessment districts in Burkina Faso, Haiti and Zambia, 2008

Fig. 2.3. Percentage of women with HIV testing and counselling and percentage of women with secondary or

higher education, district comprehensive assessment districts in Burkina Faso, Haiti and Zambia, 2008


Fig. 2.4. Percentage of women and men receiving an HIV test and test results in the 12 months preceding the survey in

countries with repeat population surveys, 2003–2008

Fig. 2.4. Percentage of women and men receiving an HIV test and test results in the 12 months preceding the survey in

countries with repeat population surveys, 2003–2008


Fig. 2.5. Percentage of women and men (≥15 years) who had ever received an HIV test and test results, South Africa, 2002,

2005 and 2008

Fig. 2.5. Percentage of women and men (≥15 years) who had ever received an HIV test and test results, South Africa, 2002,

2005 and 2008


Fig. 3.1. Situation analysis of harm reduction interventions in the Middle East and North Africa at baseline, 2008

Fig. 3.1. Situation analysis of harm reduction interventions in the Middle East and North Africa at baseline, 2008


Fig. 3.2. Blood donation per 1000 population, 2007Fig. 3.2. Blood donation per 1000 population, 2007


Fig. 4.1. Number of people receiving antiretroviral therapy in low- and middle-income countries, by region, 2002–2008

Fig. 4.1. Number of people receiving antiretroviral therapy in low- and middle-income countries, by region, 2002–2008


Fig. 4.2. Measuring attrition from antiretroviral therapy programmes

Fig. 4.2. Measuring attrition from antiretroviral therapy programmes


Fig. 4.3. Retention on antiretroviral therapy at 12 months after initiation of treatment in 61 low- and middle-income countries

by region, 2008

Fig. 4.3. Retention on antiretroviral therapy at 12 months after initiation of treatment in 61 low- and middle-income countries

by region, 2008


Fig. 4.4. 12-month retention of people receiving antiretroviral therapy in selected treatment sites, Papua New Guinea, 2008Fig. 4.4. 12-month retention of people receiving antiretroviral therapy in selected treatment sites, Papua New Guinea, 2008


Fig. 4.5. Trends in retention on antiretroviral therapy in low- and middle-income countries by region, 2008

Fig. 4.5. Trends in retention on antiretroviral therapy in low- and middle-income countries by region, 2008


Fig. 4.6. Trends over time in the median CD4 count at baseline count of 36 715 adults starting antiretroviral therapy between

2001 and 2006

Fig. 4.6. Trends over time in the median CD4 count at baseline count of 36 715 adults starting antiretroviral therapy between

2001 and 2006


Fig. 4.7. Antiretroviral therapy coverage and all-cause mortality in South Africa, 2003–2006

Fig. 4.7. Antiretroviral therapy coverage and all-cause mortality in South Africa, 2003–2006


Fig. 4.8. Countries implementing at least one element of the WHO Global Strategy for the Prevention and Assessment of HIV Drug Resistance and locations of HIV drug resistance

testing laboratories, February 2009

Fig. 4.8. Countries implementing at least one element of the WHO Global Strategy for the Prevention and Assessment of HIV Drug Resistance and locations of HIV drug resistance

testing laboratories, February 2009


Fig. 4.9. Main first-line antiretroviral regimens used among 2.4 million adults in 36 low- and middle-income countries,

December 2008

Fig. 4.9. Main first-line antiretroviral regimens used among 2.4 million adults in 36 low- and middle-income countries,

December 2008


Fig. 4.10. Main second-line antiretroviral regimens used among adults (n=51 135) in 36 low- and middle-income countries,

December 2008

Fig. 4.10. Main second-line antiretroviral regimens used among adults (n=51 135) in 36 low- and middle-income countries,

December 2008


Fig. 4.11. First-line regimens used among children (n=177 064) in 36 low- and middle-income countries, December 2008

Fig. 4.11. First-line regimens used among children (n=177 064) in 36 low- and middle-income countries, December 2008


Fig. 4.12. Second-line regimens used among children (n=5997) in 35 low- and middle-income countries, December 2008

Fig. 4.12. Second-line regimens used among children (n=5997) in 35 low- and middle-income countries, December 2008


Fig. 4.13. Median annual cost (in US dollars) of first-line antiretroviral drug regimens in low-income countries by year,

2004–2008

Fig. 4.13. Median annual cost (in US dollars) of first-line antiretroviral drug regimens in low-income countries by year,

2004–2008


Fig. 4.14. Median annual cost (in US dollars) of first-line antiretroviral drug regimens in lower-middle-income countries

by year, 2004–2008

Fig. 4.14. Median annual cost (in US dollars) of first-line antiretroviral drug regimens in lower-middle-income countries

by year, 2004–2008


Fig. 4.15. Median price (in US dollars) of first-line antiretroviral drug regimens in upper-middle-income countries by year,

2004–2008

Fig. 4.15. Median price (in US dollars) of first-line antiretroviral drug regimens in upper-middle-income countries by year,

2004–2008


Fig. 4.16. Estimated HIV prevalence (%) among people newly infected with TB, 2007

Fig. 4.16. Estimated HIV prevalence (%) among people newly infected with TB, 2007


Fig. 4.17. Rates of HIV testing among people with TB in countries in sub-Saharan Africa, 2004–2007

Fig. 4.17. Rates of HIV testing among people with TB in countries in sub-Saharan Africa, 2004–2007


Fig. 5.1. Number of low- and middle-income countries with national scale-up plans including population-based targets for preventing mother-to-child transmission and for HIV care and

treatment for children, by region, 2008

Fig. 5.1. Number of low- and middle-income countries with national scale-up plans including population-based targets for preventing mother-to-child transmission and for HIV care and

treatment for children, by region, 2008


Fig. 5.2. Percentage of women and men aged 15–49 years with comprehensive knowledgea of HIV in countries with recent

population-based surveys (2007–2008)

Fig. 5.2. Percentage of women and men aged 15–49 years with comprehensive knowledgea of HIV in countries with recent

population-based surveys (2007–2008)


Fig. 5.3. Reported percentage condom use at last sexual intercourse among women 15–49 years old who had sex in the past year by five-year age groups in selected population-based

surveys, 2005–2007

Fig. 5.3. Reported percentage condom use at last sexual intercourse among women 15–49 years old who had sex in the past year by five-year age groups in selected population-based

surveys, 2005–2007


Fig. 5.4. Unmet need for family planning among married women 15–49 years old (%) in countries with a generalized

epidemic, 2006–2008

Fig. 5.4. Unmet need for family planning among married women 15–49 years old (%) in countries with a generalized

epidemic, 2006–2008


Fig. 5.5. Percentage of pregnant women who received an HIV test in low- and middle-income countries by region, 2004–

2008a

Fig. 5.5. Percentage of pregnant women who received an HIV test in low- and middle-income countries by region, 2004–

2008a


Fig. 5.6. Percentage of pregnant women who received an HIV test in Malawi, 2004–2008

Fig. 5.6. Percentage of pregnant women who received an HIV test in Malawi, 2004–2008


Fig. 5.7. Percentage of pregnant women with HIV receiving antiretrovirals for preventing mother-to-child transmission of HIV in low- and middle-income countries by region, 2004–2008

Fig. 5.7. Percentage of pregnant women with HIV receiving antiretrovirals for preventing mother-to-child transmission of HIV in low- and middle-income countries by region, 2004–2008


Fig. 5.8. Percentage of pregnant women living with HIV who received antiretrovirals to prevent mother-to-child

transmission of HIV in Côte d’Ivoire, 2005–2008

Fig. 5.8. Percentage of pregnant women living with HIV who received antiretrovirals to prevent mother-to-child

transmission of HIV in Côte d’Ivoire, 2005–2008


Fig. 5.9. Percentage of pregnant women living with HIV receiving antiretrovirals to prevent the mother-to-child transmission of HIV in 20 countries with the highest HIV

disease burden among pregnant women (in descending order), 2008

Fig. 5.9. Percentage of pregnant women living with HIV receiving antiretrovirals to prevent the mother-to-child transmission of HIV in 20 countries with the highest HIV

disease burden among pregnant women (in descending order), 2008


Fig. 5.10. Coverage of antiretrovirals to prevent the mother-to-child transmission of HIV, 2008

Fig. 5.10. Coverage of antiretrovirals to prevent the mother-to-child transmission of HIV, 2008


Fig. 5.11. Percentage distribution of various antiretroviral regimens provided to pregnant women in low- and medium-

income countries in 2007 and 2008, based on available data

Fig. 5.11. Percentage distribution of various antiretroviral regimens provided to pregnant women in low- and medium-

income countries in 2007 and 2008, based on available data


Fig. 5.12. Contribution of the 20 countries with the largest numbers of women needing antiretrovirals for preventing the mother-to-child transmission of HIV to the global gap to reach

80% of those in need, 2008

Fig. 5.12. Contribution of the 20 countries with the largest numbers of women needing antiretrovirals for preventing the mother-to-child transmission of HIV to the global gap to reach

80% of those in need, 2008


Fig. 5.13. Coverage of antiretroviral prophylaxis among infants born to mothers living with HIV in low- and middle-income

countries by region, 2008

Fig. 5.13. Coverage of antiretroviral prophylaxis among infants born to mothers living with HIV in low- and middle-income

countries by region, 2008


Fig. 5.14. Percentage of pregnant women living with HIV and infants born to them who received antiretrovirals for preventing mother-to-child transmission, 2004–2008

Fig. 5.14. Percentage of pregnant women living with HIV and infants born to them who received antiretrovirals for preventing mother-to-child transmission, 2004–2008


Fig. 5.15. Average age of infants at their first HIV DNA test in Namibia in weeks, 2006–2008

Fig. 5.15. Average age of infants at their first HIV DNA test in Namibia in weeks, 2006–2008


Fig. 5.16. Percentage of children receiving antiretroviral therapy in low- and middle-income countries, 2005–2008Fig. 5.16. Percentage of children receiving antiretroviral therapy in low- and middle-income countries, 2005–2008

Documents

Towards universal access: scaling up priority HIV/AIDS interventions in the health sector Progress report 2009 Slide set – six summary data slides and